DNA X, Inc. regained compliance with Nasdaq’s $2.5 million stockholders’ Equity requirement under Listing Rule 5550. Investors still face a defined listing risk: the securities remain subject to delisting through November 18, 2026, and mandatory Panel monitoring continues through August 28, 2027 if Nasdaq rules are not maintained.

Key Highlights

  • Nasdaq’s Hearings Panel notified DNA X of its compliance decision on August 28, 2026.
  • A mandatory Nasdaq Panel monitor will oversee DNA X through August 28, 2027.
  • A mandatory Panel monitor applies until August 28, 2027 under Nasdaq Listing Rule 5815.

The restored status is conditional: DNA X (NASDAQ: SONM)’s securities remain subject to delisting if all Nasdaq Listing Rules are not maintained through November 18, 2026.

Nasdaq Panel Sets Compliance Conditions

Nasdaq’s Hearings Panel sent the compliance notice on August 28, 2026. A mandatory Panel monitor will remain in place until August 28, 2027, under Nasdaq Listing Rule 5815. The monitoring period applies to the Stockholders’ Equity Requirement.

Repeat Deficiency Could Trigger Delisting

DNA X would not be permitted to submit a compliance plan for that deficiency, receive additional time to regain compliance, or use an applicable cure or compliance period.

Peers Moving on This News